August 02, 2019 Strike two for overheated South Korean biotech Pexa-Vec fails earlier than expected, dealing exuberant South Korean biotech investors and the oncolytic virus field another blow.
October 24, 2018 Esmo 2018 – Adaptimmune gets the wooden spoon The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
September 21, 2018 Oncolytics prepares to tap US investors The tiny biotech has wasted no time in jumping on the oncolytic virus deal-making bandwagon, but dilution is nevertheless still likely.